An Engineering Biology company dedicated to making diagnostic testing better, faster and more affordable, announced it has been awarded funding from the U.S. Defense Threat Reduction Agency (DTRA) to develop a rapid response platform for ultra-fast, ultra-sensitive and field-deployable diagnostics. Sherlock, the sole awardee, will leverage the power of its CRISPR- and Synthetic Biology-based platforms to create diagnostic tools that enable members of the military to rapidly identify biothreats and infectious disease agents.
“We are delighted to be recognized by DTRA for the advanced state of our technology and development efforts. This support will further our mission to harness the power of CRISPR and synthetic biology to develop diagnostic tools that enable effective decision making in any environment at any time,” said Rahul K. Dhanda, Sherlock’s co-founder, president and CEO. “This funding will enable our team to continue to make important progress advancing our platform, while also addressing an urgent need to rapidly identify pathogenic agents and other biothreats.”
The multiyear grant will accelerate the company’s development of infectious disease diagnostic tests for decentralized settings, such as the battlefield. Further, the support will help the company refine its deep learning and bioinformatics tools for rapid definition and deployment of molecular diagnostic tests.
“When we published the call for a new class of rapid diagnostics, we were optimistic that we would identify both a technology and an organization that could deliver a significant leap forward in testing for biothreat and battlefield settings through initiatives driven by the Defense Innovation Unit,” said Charles Hong, a science and technology manager for the Detection and Diagnostics Division at DTRA. “We are pleased to support Sherlock in its efforts to create novel CRISPR- and synthetic biology-based diagnostic tests that will be sensitive, fast and easily deployable in any setting.”
The Defense Innovation Unit identifies commercial industry solutions to support the U.S. military, and through this process, the organization facilitated finding a new class of rapid diagnostic solutions on behalf of DTRA.
“This funding provides important validation for the versatility of Sherlock’s platform, and our ability to develop simple, impactful diagnostic tools that can be applied in field-based settings,” said William Blake, Ph.D., Sherlock’s chief technology officer. “We are grateful to DTRA for this award and look forward to working with the agency in support of their mission to enable rapid responses to potential threats and crises.”
Related Reports and Monitors
Organs-On-Chips Market and Technology Landscape 2019
Market & Technology
Status of the Microfluidics Industry 2019
Market & Technology